FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer
October 23, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with...
PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product
October 16, 2019 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Oct. 16, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and Drug...
Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
October 08, 2019 09:00 ET
|
Rafael Pharmaceutical Inc.
Cranbury, NJ, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
PharmaCyte Biotech's Pancreatic Cancer Therapy Production in Final Days of Key Manufacturing Run
September 23, 2019 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Sept. 23, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) and its partner, Austrianova, along with the company’s cellular biologist, David Judd, are all more confident than...
DrugCendR Inc. Announces the Appointment of Dr. Daniel Von Hoff as Clinical Advisor
August 20, 2019 13:17 ET
|
DrugCendR Inc.
LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr....
AB Science fait le point sur le programme clinique du masitinib
August 05, 2019 01:31 ET
|
AB Science
Paris, 5 août 2019, 7h30 Point sur le programme clinique du masitinib AB Science SA (NYSE Euronext - FR0010557264 - AB) fait le point sur le programme clinique du masitinib. Les points...
AB Science provides an update on its masitinib clinical program
August 05, 2019 01:31 ET
|
AB Science
Paris, August 5 2019, 7.30am Update on masitinib clinical program AB Science SA (NYSE Euronext - FR0010557264 - AB) provides an update on its masitinib clinical program. The key points of...
Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
July 18, 2019 10:40 ET
|
Rafael Pharmaceutical Inc.
Cranbury, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting
June 01, 2019 09:00 ET
|
Bellicum Pharmaceuticals, Inc.
Data provides further evidence that GoCAR-T® technology boosts expansion and persistence of therapeutic T cells in patients T cell expansion and persistence greater in patients who received...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2019 16:14 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...